Merck (MRK)

84.86 -0.41 (0.48%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/3/20 *Est.)
- M&A (6/30/19 *Est)

Latest Headlines

Merck (MRK) Reports EC Approval for Two New Regimens of KEYTRUDA (pembrolizumab) as 1st-Line Treatment for Metastatic or Unresectable Recurrent HNSCC November 20, 2019 6:48 AM - StreetInsider European Commission Approves Two New Regimens of Merck’s KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) November 20, 2019 6:45 AM - BizWire Merck KGaA, Darmstadt, Germany, Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations November 20, 2019 2:00 AM - PR NewsWire Merck (MRK) Raises Quarterly Dividend 10.9% to $0.61; 2.9% Yield November 19, 2019 12:44 PM - StreetInsider Merck Announces First-Quarter 2020 Dividend November 19, 2019 12:43 PM - BizWire Merck (MRK), Bayer’s Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure November 18, 2019 6:31 AM - StreetInsider Merck and Bayer’s Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure November 18, 2019 6:30 AM - BizWire Merck (MRK) PT Raised to $104 at Guggenheim November 15, 2019 7:17 AM - StreetInsider Merck's (MRK) BRAVECTO PLUS for Cats Receives Approval from US FDA November 15, 2019 6:46 AM - StreetInsider BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats Receives Approval from US Food and Drug Administration November 15, 2019 6:45 AM - BizWire US FDA Accepts Regulatory Submission of New Drug Application for Selumetinib in Neurofibromatosis Type 1 (NF1) and Grants Priority Review November 14, 2019 6:55 AM - BizWire AstraZeneca (AZN), Merck (MRK) announce FDA has accepted NDA and granted Priority Review for selumetinib for paediatric patients with NF1 November 14, 2019 6:29 AM - StreetInsider NewLink Genetics (NLNK) Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 November 12, 2019 9:02 AM - StreetInsider NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®) November 12, 2019 9:01 AM - Globe NewsWire NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®) November 12, 2019 9:01 AM - StreetInsider MilliporeSigma Licenses CRISPR Gene-Editing Technology to Evotec November 12, 2019 8:00 AM - PR NewsWire Gossamer Bio (GOSS) Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA November 12, 2019 7:12 AM - StreetInsider BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th November 12, 2019 6:30 AM - Globe NewsWire Merck's (MRK) ERVEBO Ebola Zaire Vaccine Granted Conditional Approval in European Union November 11, 2019 3:02 PM - StreetInsider Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union November 11, 2019 3:00 PM - BizWire EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial November 8, 2019 8:00 AM - PR NewsWire Wells Fargo taps Bill Daley, former White House official, head of public affairs November 7, 2019 11:11 AM - StreetInsider NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate Update November 6, 2019 8:01 AM - Globe NewsWire NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate Update November 6, 2019 8:00 AM - StreetInsider Oncolytics Biotech (ONCY) Reports Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma November 6, 2019 7:27 AM - StreetInsider Form 10-Q Merck & Co., Inc. For: Sep 30 November 5, 2019 4:44 PM - SEC Filing Form 4 Merck & Co., Inc. For: Oct 30 Filed by: MIZELL STEVEN November 1, 2019 5:08 PM - SEC Filing Form 4 Merck & Co., Inc. For: Oct 30 Filed by: Nally Michael November 1, 2019 5:08 PM - SEC Filing Form 4 Merck & Co., Inc. For: Oct 30 Filed by: Clyburn Frank November 1, 2019 5:06 PM - SEC Filing Form 4 Merck & Co., Inc. For: Oct 30 Filed by: Scholefield James H November 1, 2019 5:04 PM - SEC Filing Bristol-Myers posts better-than-expected results, Opdivo growth slows October 31, 2019 7:08 AM - StreetInsider Merck (MRK) losses bid to revive $2.5B verdict against Gilead Sciences (GILD) - Bloomberg October 30, 2019 9:29 AM - StreetInsider Merck (MRK) PT Raised to $102 at Wolfe Research October 30, 2019 8:47 AM - StreetInsider Merck (MRK) PT Raised to $100 at Mizuho Securities October 30, 2019 4:15 AM - StreetInsider Pre-Open Movers 10/29: (MRTX) (AMKR) (TXRH) Higher (GRUB) (DBD) (BYND) Lower (more...) October 29, 2019 9:30 AM - StreetInsider Wall St. dips after S&P notches record, Fed on deck October 29, 2019 7:52 AM - StreetInsider Merck sees ongoing Keytruda strength as its sales top $3 billion in quarter October 29, 2019 6:57 AM - StreetInsider Form 8-K Merck & Co., Inc. For: Oct 29 October 29, 2019 6:50 AM - SEC Filing Merck (MRK) Tops Q3 EPS by 27c, Revenues Beat; Narrows & Raises FY19 EPS/Revenue Above Consensus October 29, 2019 6:47 AM - StreetInsider Merck Announces Third-Quarter 2019 Financial Results October 29, 2019 6:45 AM - BizWire Global stocks falter, dollar slips on potential U.S.-China trade delay October 28, 2019 8:44 PM - StreetInsider European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma October 28, 2019 2:00 PM - PR NewsWire Mizuho Downplays Merck (MRK) KEYTRUDA Competition in 1L NSCLC October 28, 2019 12:49 PM - StreetInsider Merck (MRK) Trades Lower Following AstraZeneca (AZN) Imfinzi Results, Down 0.70% October 28, 2019 11:39 AM - StreetInsider Merck (MRK) IV bid into EPS and outlook October 28, 2019 9:06 AM - StreetInsider Trade optimism, Fed rate-cut expectation sends S&P 500 to record October 28, 2019 7:35 AM - StreetInsider Merck (MRK) November weekly call option implied volatility is a 27 into EPS and outlook October 25, 2019 10:23 AM - StreetInsider Merck (MRK) option implied volatility low into EPS and outlook October 25, 2019 10:18 AM - StreetInsider S&P 500 nears record high on trade progress, upbeat Intel earnings October 25, 2019 7:52 AM - StreetInsider BriaCell Announces Voting Results of the Special Meeting of Shareholders October 24, 2019 6:30 AM - Globe NewsWire Merck (MRK) Off Worst Level, Still Down 4.3% October 22, 2019 10:43 AM - StreetInsider Exploratory Analysis Reports Efficacy and Safety of BAVENCIO® (avelumab) Over Three Years in Previously Treated Metastatic Merkel Cell Carcinoma October 22, 2019 8:00 AM - PR NewsWire NewLink Genetics (NLNK) Announces EU Regulatory Committee Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 October 21, 2019 4:55 PM - StreetInsider NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®) October 21, 2019 4:31 PM - StreetInsider NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®) October 21, 2019 4:30 PM - Globe NewsWire Mizuho Securities Reiterates Buy Rating on Merck (MRK) October 18, 2019 9:47 AM - StreetInsider Merck (MRK) Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA as First-Line Treatment for Metastatic or Unresectable Recurrent HNSCC October 18, 2019 7:02 AM - StreetInsider Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma October 18, 2019 7:00 AM - BizWire Merck (MRK) Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine October 18, 2019 6:45 AM - StreetInsider Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease October 18, 2019 6:45 AM - BizWire Vertex Pharma (VRTX) Added to BofA/Merrill LYnch US 1 List, Ferrari (RACE) and Merck (MRK) Removed October 17, 2019 8:16 AM - StreetInsider UPDATE: BofA/Merrill Lynch Reinstates Merck (MRK) at Neutral October 16, 2019 4:33 PM - StreetInsider BriaCell Announces Closing of Non-Brokered Private Placement of $568,444 October 15, 2019 5:33 PM - Globe NewsWire Citi Reiterates Buy Rating on Novartis (NVS) October 15, 2019 3:41 AM - StreetInsider Merck (MRK) weekly IV bid, call put ratio 1 to 1 October 10, 2019 10:46 AM - StreetInsider Gilead Sciences (GILD) Gains on Chatter October 10, 2019 9:40 AM - StreetInsider NexTech Appoints New Chief Financial Officer October 10, 2019 7:31 AM - StreetInsider Massive jury award against J&J highlights risks of its legal strategy October 9, 2019 9:28 AM - StreetInsider BriaCell Therapeutics Corp. to File Amendment to Management Information Circular October 8, 2019 7:00 PM - Globe NewsWire EMD Serono Announces JAMA Publication of Phase II Results of Sprifermin for Osteoarthritis Structure Modification October 8, 2019 11:25 AM - PR NewsWire Merck Issues 2018/2019 Corporate Responsibility Report October 8, 2019 8:00 AM - BizWire BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer October 7, 2019 6:30 AM - Globe NewsWire Form 4 Merck & Co., Inc. For: Sep 30 Filed by: WENDELL PETER C October 2, 2019 5:24 PM - SEC Filing Form 4 Merck & Co., Inc. For: Sep 30 Filed by: WEEKS WENDELL P October 2, 2019 5:21 PM - SEC Filing Form 4 Merck & Co., Inc. For: Sep 30 Filed by: LAZARUS ROCHELLE B October 2, 2019 5:19 PM - SEC Filing Form 4 Merck & Co., Inc. For: Sep 30 Filed by: GLOCER THOMAS H October 2, 2019 5:12 PM - SEC Filing Form 4 Merck & Co., Inc. For: Sep 30 Filed by: Coe Mary Ellen October 2, 2019 5:10 PM - SEC Filing Agilent Technologies (A) Granted Approval for First PD-L1 Companion Diagnostic in China October 2, 2019 10:44 AM - StreetInsider Merck's (MRK) KEYTRUDA Now Approved in China for First-Line Treatment of Certain Patients with Advanced NSCLC Whose Tumors Express PD-L1 October 2, 2019 6:48 AM - StreetInsider Merck’s KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 October 2, 2019 6:45 AM - BizWire Merck (MRK) Announces FDA Accepts Two Applications for its DIFICID to Treat Children with Clostridium difficile Infections October 2, 2019 6:31 AM - StreetInsider FDA Accepts Two Applications for Merck’s DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clostridium difficile Infections October 2, 2019 6:30 AM - BizWire Merck to Hold Third-Quarter 2019 Sales and Earnings Conference Call on October 29 October 1, 2019 6:55 AM - BizWire Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month October 1, 2019 6:30 AM - Globe NewsWire AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA More Than Doubled Median rPFS in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care September 30, 2019 10:32 AM - StreetInsider LYNPARZA® (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care (7.4 vs. 3.6 months) September 30, 2019 10:30 AM - BizWire Apple and Microsoft push Wall Street higher as trade worries abate September 30, 2019 8:17 AM - StreetInsider Merck to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference September 30, 2019 6:55 AM - BizWire Merck (MRK) Announces Pivotal RESTORE-IMI 2 Phase 3 Study of RECARBRIO in HABP/VABP Met Primary Endpoint September 30, 2019 6:49 AM - StreetInsider Pivotal RESTORE-IMI 2 Phase 3 Study of Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Met Primary Endpoint September 30, 2019 6:45 AM - BizWire Merck's (MRK) KEYTRUDA Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage TNBC September 30, 2019 6:37 AM - StreetInsider Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Nega September 29, 2019 10:30 AM - BizWire Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress September 29, 2019 2:30 AM - BizWire LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer September 28, 2019 10:30 AM - BizWire New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019 September 27, 2019 2:00 AM - PR NewsWire BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy’ Issue in Prestigious Journals September 25, 2019 6:30 AM - Globe NewsWire Novo Nordisk targets bigger slice of diabetes market with new tablet September 23, 2019 7:35 AM - StreetInsider New Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient Care September 23, 2019 2:00 AM - PR NewsWire BriaCell Announces Private Placement of up to $600,000 September 20, 2019 11:03 AM - Globe NewsWire Merck KGaA, Pfizer (PFE) Announce CHMP Adopts Positive Opinion for BAVENCIO Plus Axitinib for First-Line Treatment of Patients with Advanced RCC September 20, 2019 8:11 AM - StreetInsider CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma September 20, 2019 8:10 AM - PR NewsWire Wall Street drops after China cancels trip to Montana farmland September 20, 2019 7:42 AM - StreetInsider Merck's (MRK) PIFELTRO and DELSTRIGO Receive FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed September 20, 2019 6:46 AM - StreetInsider Merck’s PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically September 20, 2019 6:45 AM - BizWire BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA® September 19, 2019 10:00 AM - Globe NewsWire Merck (MRK) Announces FDA Approves KEYTRUDA plus LENVIMA Combination Treatment for Patients with Certain Types of Endometrial Carcinoma September 18, 2019 6:21 AM - StreetInsider FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma September 17, 2019 5:56 PM - BizWire Merck (MRK) Announces FDA Accepts its BLA and Grants Priority Review for V920 Vaccine for Ebola Zaire Virus September 17, 2019 6:46 AM - StreetInsider FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus September 17, 2019 6:45 AM - BizWire BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia September 16, 2019 6:30 AM - Globe NewsWire Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations September 11, 2019 2:30 AM - PR NewsWire UPDATE: Merck (MRK) Falls 5% on Market Open, Leading Drugmakers Lower September 10, 2019 9:34 AM - StreetInsider EMD Serono Initiates Pivotal Phase III Program for Investigational Evobrutinib in Relapsing Multiple Sclerosis September 10, 2019 8:00 AM - PR NewsWire Merck Announces First Nine “Safer Childbirth Cities” Committed to Reducing Maternal Deaths and Narrowing Disparities in the US September 10, 2019 8:00 AM - BizWire Merck (MRK) Pooled Analysis Continues to Show its KEYTRUDA in Combination with Chemotherapy Improved OS for Patients with Advanced NSCLC September 10, 2019 6:48 AM - StreetInsider Pooled Analysis Continues to Show Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Patients with Ad September 10, 2019 6:45 AM - BizWire BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49 September 9, 2019 5:33 PM - Globe NewsWire Merck (MRK) option implied volatility flat as shares sell off 3.5% September 9, 2019 11:06 AM - StreetInsider Merck (MRK) Trades at Low, Down 3.5% September 9, 2019 10:41 AM - StreetInsider Merck (MRK) Announces Pivotal New Data from its Broad Oncology Portfolio at ESMO September 9, 2019 6:48 AM - StreetInsider Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress September 9, 2019 6:45 AM - BizWire Merck to Present at the Morgan Stanley 17th Annual Global Healthcare Conference September 5, 2019 6:45 AM - BizWire Merck Foundation Launches Five-Year Initiative to Reduce Disparities in HIV Care for Vulnerable and Underserved Southeastern US Communities September 4, 2019 8:00 AM - BizWire Merck (MRK) announces EC Approves its KEYTRUDA in Combination with Inlyta as First-Line Treatment for Patients with Advanced RCC September 4, 2019 6:51 AM - StreetInsider European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC) September 4, 2019 6:45 AM - BizWire Merck (MRK) PT Raised to $105 at Societe Generale September 3, 2019 12:01 PM - StreetInsider EMD Serono to Showcase Scientific Leadership at ECTRIMS 2019 with New Data Across Multiple Sclerosis Medicines August 28, 2019 8:09 AM - PR NewsWire BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 August 27, 2019 6:30 AM - Globe NewsWire Full Article List